IDEAYA Biosciences Management
Management criteria checks 1/4
IDEAYA Biosciences' CEO is Yujiro Hata, appointed in Jun 2015, has a tenure of 9.33 years. total yearly compensation is $6.00M, comprised of 10% salary and 90% bonuses, including company stock and options. directly owns 0.8% of the company’s shares, worth €18.64M. The average tenure of the management team and the board of directors is 1.9 years and 6 years respectively.
Key information
Yujiro Hata
Chief executive officer
US$6.0m
Total compensation
CEO salary percentage | 10.0% |
CEO tenure | 9.3yrs |
CEO ownership | 0.8% |
Management average tenure | 1.9yrs |
Board average tenure | 6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$154m |
Mar 31 2024 | n/a | n/a | -US$129m |
Dec 31 2023 | US$6m | US$598k | -US$113m |
Sep 30 2023 | n/a | n/a | -US$103m |
Jun 30 2023 | n/a | n/a | -US$74m |
Mar 31 2023 | n/a | n/a | -US$68m |
Dec 31 2022 | US$3m | US$570k | -US$59m |
Sep 30 2022 | n/a | n/a | -US$53m |
Jun 30 2022 | n/a | n/a | -US$66m |
Mar 31 2022 | n/a | n/a | -US$55m |
Dec 31 2021 | US$4m | US$544k | -US$50m |
Sep 30 2021 | n/a | n/a | -US$37m |
Jun 30 2021 | n/a | n/a | -US$30m |
Mar 31 2021 | n/a | n/a | -US$31m |
Dec 31 2020 | US$2m | US$510k | -US$34m |
Sep 30 2020 | n/a | n/a | -US$40m |
Jun 30 2020 | n/a | n/a | -US$46m |
Mar 31 2020 | n/a | n/a | -US$44m |
Dec 31 2019 | US$2m | US$457k | -US$42m |
Sep 30 2019 | n/a | n/a | -US$40m |
Jun 30 2019 | n/a | n/a | -US$42m |
Mar 31 2019 | n/a | n/a | -US$38m |
Dec 31 2018 | US$2m | US$420k | -US$34m |
Compensation vs Market: Yujiro's total compensation ($USD6.00M) is above average for companies of similar size in the German market ($USD2.44M).
Compensation vs Earnings: Yujiro's compensation has increased whilst the company is unprofitable.
CEO
Yujiro Hata (50 yo)
9.3yrs
Tenure
US$5,995,440
Compensation
Mr. Yujiro S. Hata serves as an Independent Director at Enanta Pharmaceuticals, Inc. since August 29, 2021. He is a Co-Founder of IDEAYA Biosciences, Inc. and has been its Chief Executive Officer, Presiden...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 9.3yrs | US$6.00m | 0.80% € 18.6m | |
Principal Accounting Officer | 3.8yrs | US$1.41m | 0.029% € 674.5k | |
Chief Scientific Officer | 2.9yrs | US$2.76m | 0% € 0 | |
Chief Medical Officer | 1.9yrs | US$1.81m | 0% € 0 | |
Chief Technology Officer | 1.8yrs | no data | no data | |
Senior VP & General Counsel | less than a year | no data | no data | |
Vice President & Head of Human Resources | less than a year | no data | no data | |
Chief of Staff & Clinical Development | 2.6yrs | no data | no data | |
Chief Business Officer | less than a year | no data | no data |
1.9yrs
Average Tenure
57yo
Average Age
Experienced Management: 30J's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 9.3yrs | US$6.00m | 0.80% € 18.6m | |
Independent Director | 4.8yrs | US$358.02k | 0% € 0 | |
Independent Director | 9yrs | US$363.02k | 0.0051% € 117.8k | |
Independent Director | 3.7yrs | US$349.52k | 0% € 0 | |
Chair of Scientific Advisory Board | 5.7yrs | no data | no data | |
Independent Director | 6.3yrs | US$364.52k | 0% € 0 | |
Independent Director | 2.5yrs | US$350.52k | 0% € 0 | |
Member of Scientific Advisory Board | 8.4yrs | no data | no data | |
Member of Scientific Advisory Board | 5.7yrs | no data | no data | |
Member of Scientific Advisory Board | 8.4yrs | no data | no data | |
Independent Chairman of the Board | 8.8yrs | US$369.52k | 0.019% € 449.5k | |
Independent Director | 4.3yrs | US$349.52k | 0% € 0 |
6.0yrs
Average Tenure
67.5yo
Average Age
Experienced Board: 30J's board of directors are considered experienced (6 years average tenure).